{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:38:47Z","timestamp":1781235527250,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antiphospholipid syndrome (APS) is characterized by episodes of thrombosis, obstetric morbidity or both, associated with persistently positive antiphospholipid antibodies (aPL). Studying the profile of a rare disease in an admixed population is important as it can provide new insights for understanding an autoimmune disease. In this sense of miscegenation, Brazil is characterized by one of the most heterogeneous populations in the world, which is the result of five centuries of interethnic crosses of people from three continents. The objective of this study was to compare the clinical and laboratory characteristics of Brazilian vs. non-Brazilian primary antiphospholipid syndrome (PAPS) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We classified PAPS patients into 2 groups: Brazilian PAPS patients (BPAPS) and PAPS patients from other countries (non-BPAPS). They were compared regarding demographic characteristics, criteria and non-criteria APS manifestations, antiphospholipid antibody (aPL) profile, and the adjusted Global Antiphospholipid Syndrome Score (aGAPSS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 415 PAPS patients (88 [21%] BPAPS and 327 [79%] non-BPAPS). Brazilian patients were significantly younger, more frequently female, sedentary, obese, non-white, and had a higher frequency of livedo (25% vs. 10%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), cognitive dysfunction (21% vs. 8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) and seizures (16% vs. 7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.007), and a lower frequency of thrombocytopenia (9% vs. 18%, <jats:italic>p<\/jats:italic>\u2009=\u20090.037). Additionally, they were more frequently positive for lupus anticoagulant (87.5% vs. 74.6%, <jats:italic>p<\/jats:italic>\u2009=\u20090.01), and less frequently positive to anticardiolipin (46.6% vs. 73.7%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and anti-\u00df2-glycoprotein-I (13.6% vs. 62.7%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) antibodies. Triple aPL positivity was also less frequent (8% vs. 41.6%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) in Brazilian patients. Median aGAPSS was lower in the Brazilian group (8 vs. 10, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). In the multivariate analysis, BPAPS patients still presented more frequently with livedo, cognitive dysfunction and sedentary lifestyle, and less frequently with thrombocytopenia and triple positivity to aPL. They were also less often white.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study suggests a specific profile of PAPS in Brazil with higher frequency of selected non-criteria manifestations and lupus anticoagulant positivity. Lupus anticoagulant (not triple positivity) was the major aPL predictor of a classification criteria event.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-021-00222-3","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T11:02:56Z","timestamp":1635418976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository"],"prefix":"10.1186","volume":"61","author":[{"given":"Erivelton","family":"de Azevedo Lopes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Guimar\u00e3es Moreira","family":"Balbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Pengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Ugarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Michael","family":"Belmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gerosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chary","family":"Lopez-Pedrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Ramires","family":"de Jes\u00fas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ware","family":"Branch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Nalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"R\u00edos-Garc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Bertolaccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doruk","family":"Erkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-1808","authenticated-orcid":false,"given":"Danieli","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"APS ACTION","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"222_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295\u2013306.","journal-title":"J Thromb Haemost"},{"key":"222_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/ard.48.5.362","volume":"48","author":"CG Young-Macworth","year":"1989","unstructured":"Young-Macworth CG, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis. 1989;48:362\u20137.","journal-title":"Ann Rheum Dis"},{"key":"222_CR3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/0961203312437810","volume":"21","author":"D Erkan","year":"2012","unstructured":"Erkan D, Lockshin MD. APS ACTION-antiphospholipid syndrome alliance for clinical trials and international networking. Lupus. 2012;21:695\u20138.","journal-title":"Lupus"},{"key":"222_CR4","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/art.39504","volume":"68","author":"ME Alarc\u00f3n-Riquelme","year":"2016","unstructured":"Alarc\u00f3n-Riquelme ME, Ziegler JT, Molineros J, Howard TD, Moreno-Estrada A, Sanchez-Rodr\u00edguez E, et al. Genome-wide association study in an Amerindian ancestry population reveals novel systemic lupus erythematosus risk loci and the role of European admixture. Arthritis Rheumatol. 2016;68:932\u201343.","journal-title":"Arthritis Rheumatol"},{"key":"222_CR5","doi-asserted-by":"publisher","first-page":"e83926","DOI":"10.1371\/journal.pone.0083926","volume":"9","author":"DF Durso","year":"2014","unstructured":"Durso DF, Bydlowski SP, Hutz MH, Suarez-Kurtz G, Magalh\u00e3es TR, Pena SDJ. Association of genetic variants with self-assessed color categories in Brazilians. PLoS ONE. 2014;9:e83926.","journal-title":"PLoS ONE"},{"key":"222_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijcard.2017.02.155","volume":"240","author":"M Radin","year":"2017","unstructured":"Radin M, Schreiber K, Costanzo P, Cecchi I, Rocatello D, Baldovino S, et al. The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. Int J Cardiol. 2017;240:72\u20137.","journal-title":"Int J Cardiol"},{"key":"222_CR7","first-page":"31","volume":"28","author":"F Signorelli","year":"2019","unstructured":"Signorelli F, Tupinamb\u00e1 H, Jesus G, Balbi GGM, Levy R. Thrombocytopenia is highly associated with specific antiphospholipid antibodies profile (P24). Lupus. 2019;28:31.","journal-title":"Lupus"},{"key":"222_CR8","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","volume":"101","author":"M Galli","year":"2003","unstructured":"Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827\u201332.","journal-title":"Blood"},{"key":"222_CR9","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1111\/jth.15047","volume":"18","author":"KMJ Devreese","year":"2020","unstructured":"Devreese KMJ, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, et al. Guidance for the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020;18:2828\u201339.","journal-title":"J Thromb Haemost"},{"key":"222_CR10","doi-asserted-by":"publisher","DOI":"10.1055\/a-1344-4271","author":"D Yin","year":"2020","unstructured":"Yin D, de Groot PG, Ninivaggi M, Devreese KMJ, de Laat B. Clinical relevance of isolated lupus anticoagulant positivity in patients with thrombotic antiphospholipid syndrome. Thromb Haemost. 2020. https:\/\/doi.org\/10.1055\/a-1344-4271.","journal-title":"Thromb Haemost"},{"key":"222_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/0961203309360541","volume":"19","author":"M Petri","year":"2010","unstructured":"Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins\u2019 Lupus Cohort. Lupus. 2010;19:419\u201323.","journal-title":"Lupus"},{"key":"222_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.7326\/M14-2235","volume":"163","author":"J Buyon","year":"2015","unstructured":"Buyon J, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, et al. Predictors of pregnancy outcomes in patients with lupus. A cohort study Ann Intern Med. 2015;163:153\u201363.","journal-title":"A cohort study Ann Intern Med"},{"key":"222_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1160\/TH04-12-0839","volume":"93","author":"V Pengo","year":"2005","unstructured":"Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93:1147\u201352.","journal-title":"Thromb Haemost"},{"key":"222_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1365-4632.2004.01939.x","volume":"43","author":"MJN Diogenes","year":"2004","unstructured":"Diogenes MJN, Diogenes PCN, de Morais Carneiro RM, Neto CCR, Duarte FB, Holanda RRA. Cutaneous manifestations associated with antiphospholipid antibodies. Int J Dermatol. 2004;43:632\u20137.","journal-title":"Int J Dermatol"},{"key":"222_CR15","first-page":"2379","volume":"33","author":"IW Uthman","year":"2006","unstructured":"Uthman IW, Khamashta MA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol. 2006;33:2379\u201382.","journal-title":"J Rheumatol"},{"key":"222_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1177\/0961203317734924","volume":"27","author":"U Ilgen","year":"2018","unstructured":"Ilgen U, Yayla ME, Ates A, Okatan IE, Yurteri EU, Torgultap M, et al. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus. Lupus. 2018;27:665\u20139.","journal-title":"Lupus"},{"key":"222_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/0961203310395052","volume":"20","author":"R Cervera","year":"2011","unstructured":"Cervera R, Tektonidou MG, Espinosa G, Cabral AR, Gonz\u00e1lez EB, Erkan D, et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus. 2011;20:174\u201381.","journal-title":"Lupus"},{"key":"222_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/rheumatology\/keaa252","volume":"60","author":"RF Rosa","year":"2021","unstructured":"Rosa RF, Ugolini-Lopes MR, Gandara APR, Vendramini MBG, Campanholo KR, Dutra L, et al. Cognitive dysfunction and serum levels of brain-derived neurotrophic factor (BDNF) in primary anti-phospholipid syndrome (PAPS). Rheumatology (Oxford). 2021;60:179\u201387.","journal-title":"Rheumatology (Oxford)"},{"key":"222_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.autrev.2010.10.004","volume":"10","author":"G Medina","year":"2011","unstructured":"Medina G, Guti\u00e9rrez-Moreno AL, Vera-Lastra O, Saavedra MA, Jara LJ. Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev. 2011;10:214\u20137.","journal-title":"Autoimmun Rev"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-021-00222-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-021-00222-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-021-00222-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T11:03:46Z","timestamp":1635419026000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-021-00222-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["222"],"URL":"https:\/\/doi.org\/10.1186\/s42358-021-00222-3","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"assertion":[{"value":"9 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed using data from the APS ACTION Registry. During recruitment, each center received ethical approval of your local committee. The study protocol was submitted for approval by the APS ACTION Committee. All patients included in this study signed a written informed consent during APS ACTION Registry recruitment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests regarding this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}